RxDoctor Payments Data

Marilyn Rosca

Gerontology · Lakewood, CANPI 1194177188

Payments from drug & device makers

$526in general payments, 2019–2025

Across 5 payments — averaging $105.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$149
  • ANI Pharmaceuticals, Inc.$132
  • AstraZeneca$125
  • Ardelyx, Inc.$120

What the payments were for

  • Food & beverage$526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen2$149
ANI Pharmaceuticals, Inc.1$132
AstraZeneca1$125
Ardelyx, Inc.1$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$526 in reported general payments places this provider in the 60th percentile of 348 gerontology providers in California.

See all gerontology providers in California

Medicare billing

Part B allowed, 2024
$247,442
Medicare patients
419
Services billed
3,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide36$82,550
ClinolipidFat Emulsion/Olive/Soy/Phospho72$25,775
Sevelamer Hcl15$15,872
ProsolParenteral Amino Acid 20% No.184$13,344
LokelmaSodium Zirconium Cyclosilicate22$12,603
Sevelamer Carbonate73$8,574
Calcium Acetate78$4,882
Sodium Polystyrene Sulfonate26$2,013
Nifedipine ErNifedipine43$1,101
Midodrine Hcl13$985
Hydralazine Hcl15$229
Labetalol Hcl11$227
Ropinirole Hcl26$183
Lactulose12$152
Omeprazole16$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$125$12,60322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 348 gerontology providers in California.

Other gerontology in Lakewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →